Sound waves take aim at pancreatic tumors: new trial tests HIFU

NCT ID NCT06211933

Terminated Disease control Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests a procedure called High-Intensity Focused Ultrasound (HIFU) for people with pancreatic cancer that cannot be removed by surgery. The study has two parts: first, checking how safe the procedure is, and second, seeing if it helps patients live longer. About 26 participants will receive a single HIFU treatment directly on the tumor during surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: High-Intensity Focused Ultrasound (HIFU)
What this could lead to: If successful, HIFU could offer a new treatment option for patients with pancreatic tumors that cannot be surgically removed, potentially improving survival.
What could go wrong: This is an early-phase trial with only 26 participants, and the study is currently suspended. The procedure carries risks of serious complications, and it is unclear if it will meaningfully extend life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm neoplasm pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-RESECTABLE PANCREAS CARCINOMA

Contacts and locations

Locations

CHU Estaing

Clermont-Ferrand, Auvergne-Rhône-Alpes, 63003, France
Centre Léon Bérard

Lyon, Auvergne-Rhône-Alpes, 69008, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.